Sodium Tetradecyl Sulfate
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Sodium Tetradecyl Sulfate
- Pharmacist Assessment Report
- Sodium Tetradecyl Sulfate: From Varicose Disease to Esophageal Varices with Bleeding
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Sodium Tetradecyl Sulfate: From Varicose Disease to Esophageal Varices with Bleeding
One-Sentence Summary
Sodium tetradecyl sulfate (STS) is an injectable sclerosant originally used to treat varicose veins. The TxGNN model predicts it may be effective for esophageal varices with bleeding, and the evidence consists of 20 publications (including 2 randomized comparisons of sclerosants and 1 meta-analysis) but no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Varicose disease (the Canadian licence records contain no indication text) |
| Predicted New Indication | Esophageal varices with bleeding |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L2 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, STS is a detergent sclerosant. It damages the vascular endothelium, which causes thrombosis and fibrosis and closes the vessel.
This is the same mechanism that underlies its use in varicose veins. Esophageal varices are also dilated veins, so closing them with a sclerosant injected through an endoscope is a direct extension of the original use. The literature also shows STS foam being used in balloon-occluded retrograde transvenous obliteration (BRTO) of gastric varices.
An important caveat applies. Endoscopic band ligation and drug therapy have largely replaced sclerotherapy as standard care. Serious complications such as esophageal perforation and strictures are well documented. The evidence level is L2 rather than L1 because no Phase 3 trial registry entry was provided, and the randomized studies are old, small and mostly compare one sclerosant against another. This judgment is based on titles and short abstracts only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 8886633 | 1996 | RCT | Endoscopy | Hypertonic glucose water vs STS for gastric variceal bleeding in advanced cirrhosis |
| 1734694 | 1992 | RCT | Am J Gastroenterol | STS vs polidocanol in 52 patients with variceal bleeding; varices eradicated in 88% in each group, with no significant difference |
| 2279644 | 1990 | RCT | Gastrointest Endosc | STS vs sodium morrhuate in 41 patients with acute variceal bleeding; mortality 38% vs 25% (not significant) |
| 11323580 | 2001 | RCT | Gastrointest Endosc | Band ligation alone vs ligation followed by adjuvant sclerotherapy for esophageal varices |
| 7942715 | 1994 | Meta-analysis | Am J Gastroenterol | Prophylactic endoscopic sclerotherapy and survival; addresses sclerotherapy in general, not STS specifically |
| 30170340 | 2019 | Review | J Gastroenterol Hepatol | Recent development of BRTO, including use of STS as a sclerosant |
| 2191592 | 1990 | Review | Am J Gastroenterol | Critical appraisal of sclerosants for variceal sclerotherapy |
| 2920638 | 1989 | Safety cohort | Dig Dis Sci | 900 STS sclerotherapy procedures in 170 patients; esophageal perforation confirmed in 5 (2.9%) |
| 21353984 | 2011 | Case series | J Vasc Interv Radiol | Initial experience with BRTO using STS foam for bleeding gastric varices |
| 37745308 | 2023 | Clinical study | Diagn Interv Radiol | Antegrade foam sclerotherapy for portal hypertensive variceal bleeding |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00511234 | TROMBOJECT 1% | Not listed | Not listed |
| 00511226 | TROMBOJECT 3% | Not listed | Not listed |
Safety Considerations
- Disease-level cautions from the knowledge graph (not label text): the knowledge graph links STS to contraindication-type relationships with thrombophlebitis, thrombophlebitis migrans, venous insufficiency, thromboangiitis obliterans, arteriosclerosis and atherosclerosis, hyperthyroidism and thyrotoxicosis (including Graves disease), hematologic disease, infectious disease, and cancer.
- Procedure-related risks reported in the literature:
- Esophageal perforation (2.9% in one series of 900 procedures).
- Esophageal strictures (15.5% in one series of 129 patients), which were managed with dilation.
- Lung injury (ARDS), reported in an animal study after intravenous sclerosant exposure.
- Balloon catheter rupture during BRTO.
- No drug interaction data were found.
Please refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanism plausibly carries over from varicose veins to esophageal varices, and randomized comparisons and decades of clinical use support it. However, the evidence is old, small and mostly compares sclerosants with each other. Band ligation and drug therapy are now the standard of care, and sclerotherapy has serious complications.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications, which are currently missing and block safety screening
- Mechanism of action data from DrugBank
- Comparison with current standard care (band ligation, beta-blockers) and a defined place in therapy, for example when ligation is not feasible or for gastric varices via BRTO
- Confirmation that the Canadian licences cover this route of use and indication, since the licence records contain no indication text
- A safety plan covering perforation, stricture and the conditions listed in the TxGNN model (deep learning) output, which may reflect similarities the model learned between related diseases, not biological evidence
Other predictions: Esophageal varices without bleeding (score 0.9997, L2) is a research question only, because the risk-benefit balance is less favorable in patients who have not bled. The remaining eight predictions (for example Steel syndrome, pseudo-von Willebrand disease and hypophosphatasia) have no trials or literature and no plausible mechanistic link, so the recommendation is Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.